Naikai Zosen Corporation (TYO:7018)

Oncternal Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	1,144	2,480	1,049	353	-918
Depreciation & Amortization	817	815	830	813	908
Loss (Gain) From Sale of Assets	31	44	50	70	47
Loss (Gain) From Sale of Investments	-18	-	-466	-	7
Other Operating Activities	1,259	-2,806	-1,262	1,128	-196
Change in Accounts Receivable	-9,853	2,607	-6,781	5,812	-824
Change in Inventory	-186	532	-684	-113	190
Change in Accounts Payable	-4	-3,672	450	1,495	-2,496
Change in Other Net Operating Assets	1,435	6,747	432	1,222	-815
Operating Cash Flow	-5,375	6,747	-6,382	10,780	-4,097
Capital Expenditures	-1,210	-787	-1,495	-1,501	-1,515
Investment in Securities	27	-	1,336	-	-
Other Investing Activities	-18	-37	-90	-177	-16
Investing Cash Flow	-1,201	-824	-249	-1,678	-1,531
Long-Term Debt Issued	-	2,847	2,820	2,847	4,840
Short-Term Debt Repaid	-250	-	-	-	-
Long-Term Debt Repaid	-3,025	-3,307	-3,145	-3,125	-3,080
Total Debt Repaid	-3,275	-3,307	-3,145	-3,125	-3,080
Net Debt Issued (Repaid)	-3,275	-460	-325	-278	1,760
Dividends Paid	-168	-67	-33	-	-50
Other Financing Activities	-1	-1	-1	-	-1
Financing Cash Flow	-3,444	-528	-359	-278	1,709
Foreign Exchange Rate Adjustments	-81	91	26	8	-
Miscellaneous Cash Flow Adjustments	-2	-	-1	-1	-
Net Cash Flow	-10,103	5,486	-6,965	8,831	-3,919
Free Cash Flow	-6,585	5,960	-7,877	9,279	-5,612
Free Cash Flow Margin	-14.75%	12.85%	-20.94%	28.09%	-18.03%
Free Cash Flow Per Share	-3887.25	3518.30	-4647.20	5474.34	-3310.91
Cash Interest Paid	79	100	93	102	100
Cash Income Tax Paid	172	329	276	4	29
Levered Free Cash Flow	-7,090	5,650	-7,385	9,455	-5,038
Unlevered Free Cash Flow	-7,039	5,711	-7,327	9,517	-4,977
Change in Working Capital	-8,608	6,214	-6,583	8,416	-3,945

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.